Research programme: Alzheimer's disease gene therapy - Amarantus Bioscience Holdings/University of Leipzig

Drug Profile

Research programme: Alzheimer's disease gene therapy - Amarantus Bioscience Holdings/University of Leipzig

Alternative Names: P16 gene therapy - Amarantus Bioscience Holdings/University of Leipzig

Latest Information Update: 12 Aug 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Leipzig
  • Developer Amarantus Bioscience Holdings; University of Leipzig
  • Class Gene therapies
  • Mechanism of Action Cell cycle modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Alzheimer's disease

Most Recent Events

  • 01 Aug 2014 Amarantus Bioscience Holdings acquires an exclusive option to in-license the intellectual property covering Alzheimer's disease gene therapy
  • 01 Aug 2014 Early research in Alzheimer's disease in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top